New Cream Aims to Bridge the ‘Orgasm Gap’ for Women

The launch of a new cream, Myregyna, seeks to address the challenges faced by midlife women experiencing low libido. Developed by Dr Iona Weir, a cellular biologist from New Zealand, this product aims to alleviate issues related to vaginal atrophy, a common consequence of menopause. Following a year of clinical trials concluding in May 2023, Myregyna became available to consumers worldwide this summer.

Dr Weir’s journey began in 2008 when she underwent surgery with a 5% risk of inducing menopause. Within weeks, she experienced significant hormonal changes. Her gynecologist warned her about the impending challenges, which influenced Weir’s career trajectory. Previously focused on skin treatments, she shifted her attention to the sexual health of women, particularly in midlife.

Addressing a Common Issue

Research suggests that more than one in three women may experience low libido at some point in their lives. Factors contributing to this condition can include hormonal fluctuations, physical discomfort, psychological factors, and relationship challenges. As women age, the issue often intensifies, leading many to experience a lack of intimacy that can feel insurmountable.

In a video call from Auckland, Dr Weir, now 59, shared insights into her product. She explained how Myregyna works to restore vaginal health by reversing tissue thinning and enhancing nerve sensitivity. “The nerve between the G-spot and the clitoris atrophies as women age, resulting in a loss of about 20% of nerve sensitivity,” she noted. This physiological change can diminish the intensity of orgasms, making sexual experiences less enjoyable.

Many women, she said, stop having sex due to discomfort and the emotional toll it takes. Dr Weir recalled the overwhelming response to her pilot study, with numerous women expressing their struggles with intimacy. “I had women telling me they hadn’t had sex with their husbands in ten years due to pain,” she said, highlighting the pervasive silence surrounding this issue.

The Market for Female Sexual Health Solutions

The societal stigma surrounding female sexual health is gradually lifting, with increasing discussions about women’s pleasure and intimacy. Dr Grace Hatton, a women’s health specialist, reported that 30% of women seeking help for low libido inquire about testosterone supplements, which can boost sexual desire. Sales of sexual wellness products, such as clitoral vibrators and orgasm gels, have also risen significantly, reflecting a shift in attitudes.

Despite the excitement surrounding Myregyna, Dr Weir faces challenges in bringing her product to a broader market. The cream is priced at £60 (NZ$140) for a three-month supply, and she is currently seeking a manufacturing partner to expand distribution. The potential for a successful product in this sector is substantial, given that the equivalent male product, Viagra, has generated billions in revenue since its launch in 1998.

While some medications exist, such as Addyi and Vyleesi, these solutions have limitations. Addyi, approved by the US Food and Drug Administration (FDA) in 2015, has faced criticism for its efficacy, with only 29% of users reporting positive effects. Meanwhile, Vyleesi, which requires injection shortly before sexual activity, has shown better results but remains restricted in its application.

The demand for a more effective solution continues to grow. Investment experts suggest that the market for female sexual health products could expand significantly, yet the current focus primarily targets premenopausal women, which limits broader appeal.

Dr Weir’s Myregyna, she claims, is distinct in that it offers long-term improvements to vaginal health rather than just temporary relief. Clinical trials indicate that the benefits diminish after four weeks without use, emphasizing the need for regular application.

The exploration of alternative treatments, such as kisspeptin, a hormone that stimulates reproductive hormone release, also shows promise. Initial trials indicate that kisspeptin could enhance sexual desire in both men and women by reducing self-consciousness that often hinders arousal.

As female sexual health becomes a more prominent topic, Dr Weir’s efforts represent a critical step toward closing the “orgasm gap.” While the journey to find a definitive solution for women’s libido issues continues, Myregyna offers hope for many seeking to reclaim their sexual health and intimacy.